3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
27
Melanoma
4
Sarcoma
3
Liposarcoma
3
Ovarian Neoplasms
2
Neoplasms
2
Breast Cancer Metastatic
2
Thymus Neoplasms
1
Teratoma
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Neoplastic Cells, Circulating
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasm Metastasis
1
Mesothelioma
1
Lymphoma
1
Locoregional Recurrence
1
Liposarcoma, Myxoid
1
Lipoma
1
Leukemia
1
Leiomyosarcoma
1
Hematologic Neoplasms
1
HER2-positive Advanced Breast Cancer
1
HER2 Negative Breast Cancer
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Endometrial Neoplasms
1
Diffuse Intrinsic Pontine Glioma
1
Interventions
Cyclophosphamide
178
Cytarabine
110
fludarabine phosphate
102
Methotrexate
98
Busulfan
90
Filgrastim
80
Rituximab
72
Peripheral Blood Stem Cell Transplantation
69
Cyclosporine
60
Radiotherapy
57
Etoposide
57
Mycophenolic Acid
56
Antilymphocyte Serum
56
fludarabine
55
Tacrolimus
55
Vincristine
47
Whole-Body Irradiation
44
Melphalan
42
Dexamethasone
39
Granulocyte Colony-Stimulating Factor
38
sargramostim
34
Methylprednisolone
34
Alemtuzumab
34
Daunorubicin
33
Imatinib Mesylate
32
Mercaptopurine
28
Prednisone
26
Idarubicin
26
Doxorubicin
25
Leucovorin
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Leukemia
×
ribociclib
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts